Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

Record number of medicines face supply issues amidst spiralling VPAS rebate, warns BGMA

Rising generic medicine supply issues impact four out of five NHS prescriptions

The British Generic Manufacturers’ Association (BGMA) has renewed its criticism of the government's spiralling tax on medicinal products, pointing out that more than 100 medicines are currently experiencing supply problems.


According to BGMA's monthly supply issues dashboard, which compiles data from sources like NHS England and the Department of Health and Social Care, covering both on-patent and off-patent medicines, a total of 111 products are currently experiencing supply issues.

This marks a record high, more than doubling the figures from the start of 2022. September saw the first instance of triple-digit numbers, with a total of 102.

Meanwhile, the BGMA attributed the substantial increase in shortages of branded generics to the escalating rebate rate of the Government's Voluntary Scheme for Branded Medicines Pricing and Access (VPAS).

Mark Samuels, Chief Executive of the BGMA, said, "Supply issues for generic medicines are on the rise, and patients are sadly being impacted as they represent four out of five NHS prescriptions."

"Our supply dashboard records a historic high in supply issues, with branded generics, subject to the escalating VPAS rebate rate, accounting for half. The correlation between these two issues is undeniable," he added.

VPAS aims to limit annual spending growth on branded medicines to 2 per cent, using a rebate system tied to companies' sales revenues, the BGMA said. Just two years ago, the rate was 5.1 per cent, but for 2023, it has surged to 26.5 per cent. The increase, according to BGMA, is primarily due to higher spending on on-patent medicines since 2019.

Branded generics face heat

Branded generics constitute 55 of the 111 products facing supply problems. This is half the total, despite comprising only 10 per cent of prescription products in the UK.

Branded generic treatment areas suffering issues in the latest dashboard include HRT, contraceptives, anaphylaxis, ADHD, Crohn’s disease, diabetes, lung conditions, epilepsy, acne, osteoporosis, mental health (anti-depression), heart disease, and immunosuppressants (used following transplants).

“Generics operate on high volumes and razor thin margins, so by adding a tax on revenues which has increased five-fold in two years means manufacturers have little option but to reduce or remove supplies of some products,” Samuels said. “This is not about making less profit but actually making losses as a direct result of VPAS.”

Samuels said that there's a limited supply of medicines, leading companies to prioritise allocations to countries with less stringent tax regimes. He pointed to HRT supply issues as a prime example of this practice.

"Those negotiating the next VPAS, set to run from 2024 to 2028, must address the consequences of a high rate and its disproportionate impact on off-patent products, which already face significant cost constraints due to competition," Samuels added.

"The Government must take action, or else the NHS will face higher medicine costs and shortages will become increasingly commonplace," he further said.

Last month, the BGMA cautioned that England's 42 integrated care boards (ICBs) may have to allocate an additional £37 million annually for the next five years, owing to the escalating tax rates.

More For You

Chemotherapy-free leukaemia treatment

The trial found that a combination of two cancer drugs, ibrutinib and venetoclax, could perform better than chemotherapy among patients with chronic lymphocytic leukaemia.

iStock

Chemotherapy-free leukaemia treatment shows promise during trial

In a breakthrough in leukaemia research, scientists in the UK have tested a chemotherapy-free approach, involving a combination of targeted drugs, which may offer better outcomes.

The new treatment could radically change the way chronic lymphocytic leukaemia (CLL), the most common form of leukaemia in adults, is treated.

Keep ReadingShow less
Wales ranked worst for second-trimester abortion access in the UK

Each year about 175 women travel from Wales to England for care

Wales ranked worst for second-trimester abortion access in the UK

A leading healthcare charity has revealed that Wales is the worst part of the United Kingdom for allowing surgical abortions for women.

Surgical abortion is the process removing pregnancy from the womb by inducing local anaesthesia, conscious sedation or general anaesthesia.

Keep ReadingShow less
The fund offers £150 per eligible child - for up to three children per household.

The fund offers £150 per eligible child - for up to three children per household.

Charity reopens funding to ease back to school financial pressures for community pharmacists

Community pharmacists struggling with the costs of their children going back to school can apply for funding from The Leverhulme Trade Charities Trust (LTCT)

The Trust is providing up to £100,000 of support to those working in a community pharmacy or are a registered pharmacist or pharmacy technician

Keep ReadingShow less
Germany's BioNTech to buy CureVac to boost cancer research

Both biotech companies have been working for years in the area of mRNA vaccines and treatments

Germany's BioNTech to buy CureVac to boost cancer research

Germany's BioNTech is buying domestic rival CureVac for $1.25 billion, bringing together two pharmaceutical firms specialised in mRNA technology with the goal of advancing cancer treatments.

BioNTech, which developed the first coronavirus vaccine to be approved in the West along with US pharmaceutical giant Pfizer, said the acquisition would "bring together complementary capabilities and leverage technologies".

Keep ReadingShow less
Amandeep Doll RPS  New Director of England

Amandeep Doll

RPS announces new director of England

Amandeep Doll has been named as the new director for England at the Royal Pharmaceutical Society (RPS).

The role of Director for England drives professional leadership for the pharmacy profession in England, and leads on national policy development and advocacy across England, in partnership with the English Pharmacy Board.

Keep ReadingShow less